Navigation Links
Selexis Announces Expansion of R&D License Agreement with Amgen
Date:2/20/2013

GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.  Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. 

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch , Ph.D., President and CEO of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com

 


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Incisive Surgical Announces Sale Of One-Millionth INSORB Stapler
4. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
5. UBM Canon, the Global Authority on the MedTech Industry, Announces Senior Editor for MD+DI (Medical Device & Diagnostic Industry)
6. Silver Lining Textiles, Manufacturers of Anti-microbial Under Scrub Garments for the Healthcare Industry, Announces Their Availability Through Amazon.com
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Vomaris Announces initiation of study with Walter Reed National Military Medical Centers Combat Wound Initiative
11. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 - DCGI grants ... due to Buerger,s disease - Stempeucel® becomes 5th off-the-shelf ... in the world - Buerger,s Disease (also known as ... India and Globally - Prevalence of Buerger,s ... and 2 per 10,000 persons in the European Community & ...
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at ... inspiring human interest stories, courtesy of leaders in the nursing and health care ... industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & ...
(Date:5/27/2016)... Wis. (PRWEB) , ... May 27, 2016 , ... ... $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... accepted her award on May 18 at the university’s Student Leadership Awards ceremony. ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
(Date:5/26/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... Works Award for its use of effective workplace strategies to increase business and employee ... by the Families and Work Institute (FWI) and the Society for Human Resource Management ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
Breaking Medicine News(10 mins):